Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Eric Schmidt and other AI leaders (Karpathy, Musk, Anthropic executives) have described recursive self-improvement (RSI)—AI ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Large language models appear aligned, yet harmful pretraining knowledge persists as latent patterns. Here, the authors prove current alignment creates only local safety regions, leaving global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results